Approval · Notice of Compliance 2030 · 1999
MAXALT: Notice of Compliance 2030
Issued July 16, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2030
- Date
- July 16, 1999
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- 5-ht1 receptor agonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAXALT | 02240520 | Cancelled Post Market |
| MAXALT | 02240521 | Marketed |
| MAXALT RPD | 02240519 | Marketed |
| MAXALT RPD | 02240518 | Marketed |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per WAF
- RIZATRIPTAN BENZOATE 5 MG per WAF